Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

Detalles Bibliográficos
Autores principales: Alcindor, Thierry, Jung, Sungmi, Gilbert, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293099/
https://www.ncbi.nlm.nih.gov/pubmed/34200874
http://dx.doi.org/10.3390/curroncol28030199
_version_ 1783724956716105728
author Alcindor, Thierry
Jung, Sungmi
Gilbert, Lucy
author_facet Alcindor, Thierry
Jung, Sungmi
Gilbert, Lucy
author_sort Alcindor, Thierry
collection PubMed
description A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.
format Online
Article
Text
id pubmed-8293099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82930992021-07-22 Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report Alcindor, Thierry Jung, Sungmi Gilbert, Lucy Curr Oncol Case Report A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment. MDPI 2021-06-10 /pmc/articles/PMC8293099/ /pubmed/34200874 http://dx.doi.org/10.3390/curroncol28030199 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Alcindor, Thierry
Jung, Sungmi
Gilbert, Lucy
Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title_full Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title_fullStr Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title_full_unstemmed Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title_short Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
title_sort clinical benefit from lenvatinib and pembrolizumab observed in mullerian adenosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293099/
https://www.ncbi.nlm.nih.gov/pubmed/34200874
http://dx.doi.org/10.3390/curroncol28030199
work_keys_str_mv AT alcindorthierry clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport
AT jungsungmi clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport
AT gilbertlucy clinicalbenefitfromlenvatinibandpembrolizumabobservedinmullerianadenosarcomaacasereport

Ejemplares similares